Arcus Biosciences Inc (RCUS)

$13.35 -0.02 (-0.15%)
Market Cap 1.42B
Revenue (ttm) 258.00M
Net Income (ttm) -283.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -109.69%
Debt to Equity Ratio 0.18
Volume 1,368,100
Avg Vol 825,606
Day's Range N/A - N/A
Shares Out 106.43M
Stochastic %K 69%
Beta 0.77
Analysts Strong Sell
Price Target $29.18

Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 694 6200
Address:
3928 Point Eden Way, Hayward, United States
Bobes
Bobes Oct. 3 at 8:03 PM
$RCUS good luck folks. Its now up to Terry to deliver on Monday.
0 · Reply
Mountaineer96
Mountaineer96 Oct. 3 at 6:16 PM
$RCUS just added more. I officially have an addiction to buying this stock. Hopefully my addiction pays off. My cocaine addiction never paid off just cost me a lot of money. Good luck to all!
0 · Reply
TheGunnerAB
TheGunnerAB Oct. 2 at 8:56 PM
$CRVS It's strange to have a BP executive in small bio BOD. I saw it before but usually when the BP owns lots of shares, like $GILD and $RCUS There must be something bigger going on with announcement.
1 · Reply
EmSol
EmSol Oct. 2 at 11:48 AM
$GILD $RCUS they don’t need bid for Argus, they already finance then and own the portofolio
1 · Reply
DefenseMania
DefenseMania Oct. 1 at 10:43 PM
$GILD will bid for $RCUS
1 · Reply
VAK7
VAK7 Oct. 1 at 8:41 PM
$TGTX $KRYS $RCUS $NBIS $HOOD
1 · Reply
Kanguru
Kanguru Oct. 1 at 7:28 PM
$RCUS predictions for this month?
1 · Reply
wetsalmon
wetsalmon Sep. 30 at 8:08 PM
$RCUS
1 · Reply
Dusty_Bunz
Dusty_Bunz Sep. 30 at 7:00 PM
$RCUS heading to 14?
0 · Reply
MRTunity
MRTunity Sep. 30 at 6:54 PM
$RCUS nice nearly 1M hourly candle volume on that breakout LFG 🔥
1 · Reply
Latest News on RCUS
Arcus Biosciences Announces New Employment Inducement Grants

Sep 24, 2025, 4:35 PM EDT - 10 days ago

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:59 AM EDT - 24 days ago

Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 5:08 PM EDT - 4 weeks ago

Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

Sep 2, 2025, 4:05 PM EDT - 4 weeks ago

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Aug 20, 2025, 4:05 PM EDT - 6 weeks ago

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

Aug 14, 2025, 8:07 AM EDT - 7 weeks ago

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

UEC

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

Aug 10, 2025, 9:34 AM EDT - 7 weeks ago

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

Jul 10, 2025, 8:30 AM EDT - 3 months ago

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Jun 1, 2025, 10:45 AM EDT - 4 months ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

May 6, 2025, 8:17 PM EDT - 5 months ago

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

May 6, 2025, 4:05 PM EDT - 5 months ago

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 4:05 PM EDT - 5 months ago

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Apr 22, 2025, 4:05 PM EDT - 5 months ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Apr 2, 2025, 3:48 PM EDT - 6 months ago

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Feb 26, 2025, 4:35 PM EST - 7 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Feb 25, 2025, 4:05 PM EST - 7 months ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025, 6:57 AM EST - 8 months ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Feb 18, 2025, 6:52 AM EST - 8 months ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Feb 15, 2025, 3:45 PM EST - 8 months ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Feb 10, 2025, 5:00 PM EST - 8 months ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Jan 21, 2025, 4:05 PM EST - 9 months ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

Jan 14, 2025, 10:51 PM EST - 9 months ago

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Jan 13, 2025, 8:00 AM EST - 9 months ago

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 4:05 PM EST - 10 months ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:39 PM EST - 11 months ago

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Nov 6, 2024, 4:22 PM EST - 11 months ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Nov 5, 2024, 9:00 AM EST - 11 months ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Oct 30, 2024, 9:00 AM EDT - 1 year ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Oct 24, 2024, 7:30 AM EDT - 1 year ago

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

AZN

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Sep 23, 2024, 1:53 AM EDT - 1 year ago

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HTGC

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Aug 9, 2024, 5:31 PM EDT - 1 year ago

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 5:21 PM EDT - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Jul 25, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Jul 8, 2024, 6:00 PM EDT - 1 year ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

Jun 2, 2024, 8:00 AM EDT - 1 year ago

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

GILD

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

GILD

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

May 8, 2024, 9:55 PM EDT - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

May 8, 2024, 4:02 PM EDT - 1 year ago

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024

May 2, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Apr 24, 2024, 4:00 PM EDT - 1 year ago

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

Apr 23, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 2:08 AM EST - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

Bobes
Bobes Oct. 3 at 8:03 PM
$RCUS good luck folks. Its now up to Terry to deliver on Monday.
0 · Reply
Mountaineer96
Mountaineer96 Oct. 3 at 6:16 PM
$RCUS just added more. I officially have an addiction to buying this stock. Hopefully my addiction pays off. My cocaine addiction never paid off just cost me a lot of money. Good luck to all!
0 · Reply
TheGunnerAB
TheGunnerAB Oct. 2 at 8:56 PM
$CRVS It's strange to have a BP executive in small bio BOD. I saw it before but usually when the BP owns lots of shares, like $GILD and $RCUS There must be something bigger going on with announcement.
1 · Reply
EmSol
EmSol Oct. 2 at 11:48 AM
$GILD $RCUS they don’t need bid for Argus, they already finance then and own the portofolio
1 · Reply
DefenseMania
DefenseMania Oct. 1 at 10:43 PM
$GILD will bid for $RCUS
1 · Reply
VAK7
VAK7 Oct. 1 at 8:41 PM
$TGTX $KRYS $RCUS $NBIS $HOOD
1 · Reply
Kanguru
Kanguru Oct. 1 at 7:28 PM
$RCUS predictions for this month?
1 · Reply
wetsalmon
wetsalmon Sep. 30 at 8:08 PM
$RCUS
1 · Reply
Dusty_Bunz
Dusty_Bunz Sep. 30 at 7:00 PM
$RCUS heading to 14?
0 · Reply
MRTunity
MRTunity Sep. 30 at 6:54 PM
$RCUS nice nearly 1M hourly candle volume on that breakout LFG 🔥
1 · Reply
highnihilism
highnihilism Sep. 30 at 10:20 AM
$RCUS Arcus Biosciences: 36 trades, $35K vs $141K avg (0.25x). $35K calls / $1K puts. $SPIR Spire Global: 52 trades, $39K vs $139K avg (0.28x). $35K calls / $4K puts. $DT Dynatrace: 45 trades, $43K vs $330K avg (0.13x). $34K calls / $9K puts. $MVLL Graniteshares 2X Long $MRVL Daily ETF: 45 trades, $37K vs $28K avg (1.32x). $34K calls / $3K puts.
0 · Reply
stcks
stcks Sep. 26 at 7:34 PM
$AUPH $TGTX $RCUS THE LATEST PHARMACEUTICALS TARIFFS DON'T APPLY TO COUNTRIES WITH NEGOTIATED TRADE DEALS Based on recent US trade agreements and executive orders as of September 2025, countries with negotiated deals exempt from the latest pharmaceutical tariffs include: - European Union (MFN rates for generics, cap at 15% overall, effective Sep 1) - Japan (0% on generics and ingredients) - Canada and Mexico (via USMCA, exempt from reciprocal tariffs) Other FTA partners like South Korea and Australia may qualify, but confirm via official sources.
1 · Reply
Randy2979
Randy2979 Sep. 24 at 11:23 PM
$RCUS Looks like short interest has moved up by 10%
1 · Reply
stcks
stcks Sep. 23 at 7:33 PM
$RCUS 510,222 minute 👍
1 · Reply
DCRMIA
DCRMIA Sep. 23 at 7:19 PM
$RCUS Coming🚀
0 · Reply
wetsalmon
wetsalmon Sep. 22 at 12:58 PM
$RCUS …
0 · Reply
TabJones24
TabJones24 Sep. 17 at 3:12 PM
$RCUS Why is no one talking about GILD selling
1 · Reply
pchr
pchr Sep. 17 at 12:06 PM
$RCUS any ideas why did Gilead reduce the stake of 20% in July?
4 · Reply
highnihilism
highnihilism Sep. 16 at 3:08 PM
Biotech → $RCUS Arcus Biosciences $DVAX Dynavax Technologies $MDXG Mimedx Group $VCYT Veracyte $RLAY Relay Therapeutics
0 · Reply
highnihilism
highnihilism Sep. 16 at 3:07 PM
Biotech → $PCVX Vaxcyte $CGEM Cullinan Therapeutics $AVBP Arrivent Biopharma $CLDX Celldex Therapeutics $RCUS Arcus Biosciences
0 · Reply
wetsalmon
wetsalmon Sep. 13 at 9:55 AM
$RCUS I think the data is progessively even better…he slipped up here at Citi talk… “And I think we've presented very compelling data from 120 patients that show that casdatifan is clearly a best-in-class molecule. That's been in monotherapy.” (Rosen) They haven’t presented the data yet for the 120 patients…that will be Oct 6. https://seekingalpha.com/article/4819175?gt=24b2785d4d0108e4
1 · Reply
pchr
pchr Sep. 12 at 12:33 PM
$RCUS downtrend break out, bull flagging on the daily, golden cross coming soon, chart almost identical to the one from August '19, company indicating that the data readout in October should be good, institutional ownership on ATH... can we moon yet?
0 · Reply